COMMUNIQUÉS West-GlobeNewswire

-
Marinus Pharmaceuticals Announces Data from Magnolia and Amaryllis Phase 2 Studies in Women with Postpartum Depression
23/07/2019 -
Cytokinetics Granted European Orphan Designation for Reldesemtiv for the Treatment of Spinal Muscular Atrophy
23/07/2019 -
BioCryst to Report Second Quarter 2019 Financial Results on August 6
23/07/2019 -
resTORbio Announces Early Completion of Enrollment of Phase 3 PROTECTOR 1 Trial with RTB101 in Clinically Symptomatic Respiratory Illness
23/07/2019 -
Axogen, Inc. to Report Second Quarter 2019 Financial Results and Host Conference Call on August 6, 2019
23/07/2019 -
AGTC Completes Enrollment of Third Group in the Dose Escalation Portion of the Achromatopsia CNGA3 Phase 1/2 Clinical Study
23/07/2019 -
EyePoint Pharmaceuticals Announces Data Highlighting YUTIQ® to be Presented at the 37th Annual Scientific Meeting of the American Society of Retina Specialists
23/07/2019 -
RedHill Biopharma Reports Second Quarter 2019 Financial Results and Operational Highlights
23/07/2019 -
ChromaDex Appoints Scripps Research Professor of Molecular Medicine, Brunie H. Felding, PhD, to the Scientific Advisory Board
23/07/2019 -
BriaCell Announces $350,000 Equity Investment by Board of Directors
23/07/2019 -
Qu Biologics publishes potentially paradigm-shifting results of their first randomized-placebo controlled trial for the treatment of Crohn’s disease
23/07/2019 -
RadNet, Inc. Announces Date of its Second Quarter 2019 Financial Results Conference Call
23/07/2019 -
Transactions in relation to share buyback program
23/07/2019 -
Curetis Files for U.S. FDA 510(k) Clearance of Unyvero LRT for BAL Specimens
23/07/2019 -
Sanofi signs strategic deal for exclusive US over-the-counter rights to Tamiflu® in Flu Care
23/07/2019 -
Sanofi signe un accord stratégique en vue d’obtenir les droits exclusifs de Tamiflu® dans le traitement de la grippe, sur le marché américain de l’automédication
23/07/2019 -
Idorsia announces financial results for the first half of 2019
23/07/2019 -
WW Schedules Second Quarter 2019 Earnings Conference Call
22/07/2019 -
Organogenesis Holdings Commences Offer to Exchange Class A Common Stock for any and all Outstanding Public Warrants and Consent Solicitation
22/07/2019
Pages